Sofinnova Venture Partners X, L.P. - 11 Aug 2022 Form 4 Insider Report for CinCor Pharma, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 11 Aug 2022
Net transaction value: +$15,000,000
SEC form: 4
Accepted by SEC: 15 Aug 2022, 15:46:23 UTC
Prior SEC filing: 14 Feb 2022
Next SEC filing: 08 Feb 2023
Source filing: View source filing
Reporting owner signature: Sofinnova Venture Partners X, L.P., By /s/ Nathalie Auber, Attorney-in-Fact

Key filing fact

Sofinnova Venture Partners X, L.P. filed Form 4 for CinCor Pharma, Inc. on 15 Aug 2022.

Key facts

This page summarizes Sofinnova Venture Partners X, L.P.'s Form 4 filing for CinCor Pharma, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Aug 2022, 15:46.

Change

Previous filing in this sequence was filed on 14 Feb 2022.
Current net transaction value: +$15,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CINC transaction

Common Stock

Purchase

Transaction value: $15,000,000
Shares: +500,000
Change %: +9%
Price: $30.00
Shares after: 6,073,949
Date: 11 Aug 2022
Ownership: By Sofinnova Venture Partners X, L.P.
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of such shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.